Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.
Who will be affected?
Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.
Managing COVID-19 with a Clinical Decision Support Tool in a Community Health Network: Algorithm Development and Validation
Michael P. McRae;
Isaac P. Dapkins;
Iman Sharif;
Judd Anderson;
David Fenyo;
Odai Sinokrot;
Stella K. Kang;
Nicolaos J. Christodoulides;
Deniz Vurmaz;
Glennon W. Simmons;
Timothy M. Alcorn;
Marco J. Daoura;
Stu Gisburne;
David Zar;
John T. McDevitt
ABSTRACT
Background:
The COVID-19 pandemic has resulted in significant morbidity and mortality, with large numbers of patients requiring intensive care threatening to overwhelm healthcare systems globally. There is an urgent need for a COVID-19 disease severity assessment that can assist in patient triage and resource allocation for patients at risk for severe disease.
Objective:
The goal of this study was to develop, validate, and scale a clinical decision support system and mobile app to assist in COVID-19 severity assessment, management, and care.
Methods:
Model training data from 701 patients with COVID-19 were collected across practices within the Family Health Centers network at New York University Langone Health. A two-tiered model was developed. Tier 1 uses easily available, non-laboratory data to help determine whether biomarker-based testing and/or hospitalization is necessary. Tier 2 predicts probability of mortality using biomarker measurements (CRP, PCT, D-dimer) and age. Both Tier 1 and Tier 2 models were validated using two external datasets from hospitals in Wuhan, China comprising 160 and 375 patients, respectively.
Results:
All biomarkers were measured at significantly higher levels in patients that died vs. those that were not hospitalized or discharged (P < .001). The Tier 1 and Tier 2 internal validation had AUC (95% confidence interval) of 0.79 (0.74–0.84) and 0.95 (0.92–0.98), respectively. The Tier 1 and Tier 2 external validation had AUCs of 0.79 (0.74–0.84) and 0.97 (0.95–0.99), respectively.
Conclusions:
Our results demonstrate validity of the clinical decision support system and mobile app, which are now ready to assist healthcare providers in making evidence-based decisions in managing COVID-19 patient care. The deployment of these new capabilities has potential for immediate impact in community clinics, sites whereby application of such tools could lead to improvements in patient outcomes and cost containment.
Citation
Please cite as:
McRae MP, Dapkins IP, Sharif I, Anderson J, Fenyo D, Sinokrot O, Kang SK, Christodoulides NJ, Vurmaz D, Simmons GW, Alcorn TM, Daoura MJ, Gisburne S, Zar D, McDevitt JT
Managing COVID-19 With a Clinical Decision Support Tool in a Community Health Network: Algorithm Development and Validation